Free Republic

Remember Surgisphere? That was the name of the company that allegedly gathered data from hundreds of hospitals around the world and subsequently published a research paper claiming people treated with hydroxychloroquine were more likely to die than those who were not. That paper made international news at the time, but dozens of doctors questioned the credibility of its data. The paper was eventually retracted and, as of today, it appears Surgisphere is no more: of the sad demise of the second most innovative company in medical research.— Prof Darrel Francis ☺ Mk CardioFellows Great Again (@ProfDFrancis) June 15, 2020...

The use of Real World Evidence in Covid-19 is growing, and that’s a good thing. Properly implemented, RWE has the potential to deliver solid results faster than Randomized Controlled Trials, as I explained in a .css-mckguv{-webkit-transition:background 0.25s var(--ease-in-out-quad),color 0.25s var(--ease-in-out-quad);transition:background 0.25s var(--ease-in-out-quad),color 0.25s var(--ease-in-out-quad);color:var(--theme-ui-colors-accent,#6166DC);}.css-mckguv:visited{color:var(--theme-ui-colors-accent,#6166DC);opacity:0.85;}.css-mckguv:hover,.css-mckguv:focus{-webkit-text-decoration:underline;text-decoration:underline;}previous blog post.So I couldn’t miss the largest observational study published to date on the effects of (hydroxy-)chloroquine, in 96 032 hospitalised Covid-19 patients, from an international registry comprising 671 hospitals in six continents:Mehra, M. R., Desai, S. S., Ruschitzka, F., & Patel, A. N. (2020). ‘Hydroxychloroquine or chloroquine with or without a macrolide for treatment of...

Paris (AFP) - Dozens of scientists have raised concerns over a large-scale study of hydroxychloroquine and chloroquine published in the Lancet that led to the World Health Organization suspending clinical trials of the anti-viral drugs as a potential treatment for COVID-19. Hydroxychloroquine, normally used to treat arthritis, has become one of the most high profile drugs being tested for use against the new coronavirus. This is partly because of comments by public figures including US President Donald Trump, who announced this month he was taking the drug as a preventative measure. In research published in the Lancet on May 22,...

NOTE: THIS ARTICLE HAS BEEN TRANSLATED USING GOOGLE TRANSLATE FROM FRENCH Jacques Reynes, head of the infectious diseases department at the Montpellier University Hospital, participated in studies on hydroxychloroquine: via the European Discovery and Covidoc trials, specific to Occitania. Treatment stop, Raoult controversy ... he regrets a "runaway" which will undoubtedly not allow to have indisputable data on the effectiveness of the treatment. Q: What do you think of this very critical Lancet study on the interest of hydroxychloroquine, and the cascading effects of the publication of this prestigious scientific journal published last Friday, until the ban on the use...

Questions have been raised by Australian infectious disease researchers about a study published in the Lancet which prompted the World Health Organization to halt global trials of the drug hydroxychloroquine to treat Covid-19. The study published on Friday found Covid-19 patients who received the malaria drug were dying at higher rates and experiencing more heart-related complications than other virus patients. The large observational study analysed data from nearly 15,000 patients with Covid-19 who received the drug alone or in combination with antibiotics, comparing this data with 81,000 controls who did not receive the drug. The findings prompted researchers from around...

"Scientists have raised questions about the dataset published in The Lancet last week that triggered the suspension of clinical trials around the world—and about Surgisphere Corporation, the company behind the study. " Surgisphere Corporation, the company that supplied data for a controversial study on the health risks of hydroxychloroquine for COVID-19 patients published in The Lancet last week (May 22), has found itself in the spotlight after researchers raised questions about the dataset. The Lancet study, which lists Surgisphere founder and CEO Sapan Desai as one of four coauthors, reported harmful effects tied to the anti-malaria drug hydroxychloroquine among patients...